Effects of serum homocysteine and adiponectin levels on platelet aggregation in untreated patients with essential hypertension

被引:0
作者
Hakan Ekmekçi
Özlem Balcı Ekmekçi
Serap Erdine
Hüseyin Sönmez
Yusup Ataev
Zeynep Öztürk
İlknur İşler Bütün
Çiğdem Gürel
Mine Kucur
Nurver Turfaner
Turgut Ulutin
Sevim Purisa
Vural Ali Vural
机构
[1] Istanbul University,Istanbul Medical Faculty, Bone Marrow Transplantation Unit, Department of Pediatric Haematology and Oncology
[2] Istanbul University,Cerrahpasa Medical Faculty, Department of Cardiology
[3] Istanbul University,Cerrahpasa Medical Faculty, Department of Biochemistry
[4] Istanbul University,Cerrahpasa Medical Faculty, Department of Medical Biology
[5] Istanbul University,Cerrahpasa Medical Faculty, Department of Family Medicine
[6] Istanbul University,Cerrahpasa Medical Faculty, Department of Biostatistics
来源
Journal of Thrombosis and Thrombolysis | 2009年 / 28卷
关键词
Essential hypertension; Platelet aggregation; Homocysteine; Adiponectin; Volunteers;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the present study is to determine and correlate adiponectin, homocysteine, nitric oxide, and ADP-induced platelet aggregation levels in untreated patients with essential hypertension and healthy individuals. A total of 36 individuals, 23 untreated patients with essential hypertension and 13 healthy individuals, were included in the scope of this study. Enzyme-linked immunosorbent assay (ELISA) was used to determine the serum adiponectin and TNF-α levels. The levels of serum homocysteine were measured by using competitive chemiluminescent enzyme immunoassay. Serum concentrations of hsCRP were measured by the Nephelometer. Plasma nitrite, nitrate, and total nitric oxide (NOx) levels were determined by colorimetric method. Homocysteine and hsCRP levels in patients with essential hypertension were found to be significantly higher than those in the control group (P = 0.02, P = 0.001, respectively). The avarage platelet aggregation levels in patient group were higher than control group, but there were no statistically significant differences between them (P > 0.05). In addition, in patients with essential hypertension adiponectin and nitrite levels are significantly lower than control group (P < 0.001, P = 0.045, respectively). We have also found significant correlations between nitrite-platelet aggregation amplitude, nitrite-platelet aggregation slope, nitrite-adiponectin, homocysteine-platelet aggregation amplitude, and sistolic blood pressure-platelet aggregation amplitude levels (r = −0.844; P < 0.001, r = −0.680; P = 0.011, r = 0.454; P = 0.05, r = 0.414; P = 0.05, r = 0.442; P = 0.035, respectively). Increased homocysteine and decreased adiponectin serum levels in patients with essential hypertension correlate well with changes in ADP-induced conventional platelet aggregation. This association may potentially contribute to future thrombus formation and higher risks for cardiovascular events in hypertensive patients.
引用
收藏
页码:418 / 424
页数:6
相关论文
共 195 条
[1]  
Ekmekci OB(2003)Angiotensin-converting enzyme and metals in untreated essential hypertension Biol Trace Elem Res 95 203-210
[2]  
Donma O(2007)A review of the genetics of essential hypertension Curr Opin Cardiol 22 176-184
[3]  
Tunckale A(2007)Essential hypertension Lancet 370 591-603
[4]  
Binder A(1996)Stress-induced hemodynamic and hemostatic changes in patients with systemic hypertension: effect of verapamil Clin Cardiol 19 205-211
[5]  
Messerli FH(1993)Platelet activity and salt sensitivity in the pathogenesis of systemic (essential) hypertension in black Africans Clin Exp Hypertens 15 781-796
[6]  
Williams B(2005)Is hypertension a prothrombotic state? Curr Hypertens Rep 7 168-173
[7]  
Ritz E(1999)Homocysteine metabolism Annu Rev Med 19 217-246
[8]  
Gebara OC(1997)High homocysteine levels are independently related to isolated systolic hypertension in older adults Circulation 96 1745-1749
[9]  
Jimenez AH(1999)Association between hyperhomocysteinaemia and hypertension in Sri Lankans J Int Med Res 27 38-44
[10]  
McKenna C(2003)Homocysteine and essential hypertension J Clin Pharmacol 43 1299-1306